Skip to content
Search

Latest Stories

Follow Us:
Top Stories

Slavery Claims and Drug Prices Cited in Trump’s New Tariff Plan

Trade hearings cite “forced labor” and drug‑price disputes to justify broad new tariffs.

Opinion

Slavery Claims and Drug Prices Cited in Trump’s New Tariff Plan

A look into Donald Trump’s renewed tariff strategy after a U.S. Supreme Court setback.

Getty Images, Andriy Onufriyenko

Donald Trump does not give up easily. When the U.S. Supreme Court struck down his tariffs as being illegal because he invoked so-called “emergency powers”—even though there was no emergency—did the president throw up his hands and say, “Oh well, I guess that’s the end of that?" Not in the slightest. Now the White House is back with another attempt at tariffs, apparently based on even more preposterous claims.

Trump’s Trade Commission is holding hearings to find justification for an “accelerated timeframe” for invoking a new clause, Section 301 of the Trade Act of 1974, as a vehicle for reinstating the previous tariffs. The Trade Commission is investigating unfair trade practices to determine whether “the acts, policies, or practices of a foreign country are unreasonable or discriminatory and burden or restrict U.S. commerce.”


Slavery…in the EU?

There’s nothing wrong with doing that, but here’s where it gets really peculiar in a kind of, well, Trump-ian way. The Trade Commission hearings are investigating dozens of countries, including our top trading partners like the European Union, Canada, Japan, Australia, Mexico, China, and India. More specifically, the hearings are shining a spotlight on specific trade infractions that could justify slapping tariffs on a nation. One of the potential violations is: “forced labor,” which is a nice term for: “slavery.”

Say what? The Trump administration is investigating Germany, the UK, Canada, Norway, Denmark, Japan, and Switzerland—the land of chocolate, cheese, and watches—for slavery? As the rationale for imposing tariffs?

Stretching the logic further, even if slavery isn’t occurring in the investigated country, maybe that country is trading with other countries that are…using slaves? The sketchy rationale has many a trade expert scratching their heads.

To be clear, some of the 60 nations being reviewed for slave labor might make sense, including China, Saudi Arabia, Kazakhstan, and Libya. The U.S. has long-standing sanctions against some Chinese exports because of forced labor of the Uyghur ethnic and religious minority. But for most of the other five dozen nations, it’s pretty ridiculous because those are some of the highest-ranked on ethics and corruption by Transparency International, way above Trump’s America, which is ranked a lowly 29th.

It’s also ridiculous because many of those countries, such as those in the EU, Canada, Norway, the UK, and more, have better labor practices than we have in the US. The Trump administration is clearly on a fishing expedition for whatever charges it can make—similar to when it accused Canada of exporting fentanyl to the U.S. as a reason for tariffs, when in reality Canada exports a minuscule amount, no more than the U.S. exports to Canada.

If the U.S. trade representative makes the required findings following an investigation about any individual country, the president may then impose very high tariffs or other trade restrictions on that country. Game on.

Is Trump trying to raise drug prices in other countries?

The fishing expedition doesn’t stop there. Other parts of the hearings are looking into countries’ policies that “may artificially lower drug prices, including price-fixing and discriminatory policies against U.S. technology and pharmaceutical products.” Numerous studies have found that the US allows drug companies to charge more for pharmaceuticals than just about every other developed nation. The same pill made by the same factory sells for five times the price in the US because pharmaceutical companies are price-gouging the American public.

Is the White House going to demand that international trade partners increase the price of their domestic pharmaceuticals to U.S. levels in order to avoid higher tariffs? Apparently so. The Trump administration has targeted a rebate that the UK receives from pharmaceutical companies and that they pass on to consumers to lower prices; the White House is demanding an agreement that will increase the net price that the UK pays for new medicines by 25%. How is this a win for either British or American consumers? According to Trump’s trade representative, this will ensure that higher prices for new medicines are not “materially eroded” by any rebate schemes. In other words, if countries like the UK and others don’t cooperate in increasing their pharmaceutical prices to U.S. levels, that will be the justification for slapping a tariff on that country.

Further grounds for investigation: discrimination against U.S. technology companies. In the past, this had been used, justifiably, to target China for coercing technology transfers. But now it is clearly an attack on the EU because of its passage of laws regulating Big Tech companies, including the EU’s groundbreaking Digital Services Act and Digital Markets Act, to justify retaliatory tariffs.

Tariffs vs trade surplus

Another part of this “investigation” will look into what the White House is calling “manufacturing overcapacity,” targeting 16 major economies to determine if their production policies unfairly burden U.S. commerce. Again, some of these investigations might have a degree of legitimacy, depending on the country, such as China and India. But in reality, the United States runs a trade surplus in goods with 136 countries and a trade deficit with only 97 countries. Would it then be fair for those surplus counties to slap a reciprocal tariff on the United States?

For example, the U.S. has a goods trade surplus with the Netherlands ($61B), the UK ($32B), the UAE ($24B), Spain, Belgium, Australia, Hong Kong, Brazil, Belgium, UAE, Singapore, many Latin American countries, and more. Yet most of these countries are nevertheless being targeted by this “investigation.” Not to mention that the US actually has a trade surplus in services (as opposed to goods), exporting far more services to many countries—especially in technology, financial services, and travel—than we import. While the U.S. has a massive trade deficit in goods, our consistent services surplus, which exceeded $278 billion in 2023, helps offset that imbalance.

The U.S. trade imbalance on a volume/dollar level is really with only 10 countries, in this order: China, Mexico, Vietnam, Germany, Canada, Japan, Ireland, South Korea, India, and Italy. So why then is Trump casting his net far wider than those ten?

Trump wants tariffs as a political weapon, not an economic one

None of this makes very much sense. Addressing such a broad range of alleged trade infractions to justify tariffs is like having the hometown referees officiating at the local high school basketball game. What’s clear is that what Trump really wants is the power to “negotiate” with each country, using tariffs—an economic tool—as a political cudgel to get any number of political or economic concessions. The White House wants to be able to say to countries, “Be nice to us or we will impose tariffs,” and following the Supreme Court ruling, it can no longer do that.

Before, Trump was able to do things like threaten a new tariff on Canada because he didn’t like a Canadian television ad criticizing his trade policies. Previously, the president had what has been described as “a little tariff switch” in the Oval Office that he could flip on and off anytime he wanted to. If he wakes up in the morning and he doesn’t like what a world leader has said, before he could crank the tariff dial as high as the urge struck him.

So that’s what these Trade Commission hearings are really about. Trying to find any reason or rationale, no matter how ridiculous, to return to a tariff policy that allows the president to have unilateral trade leverage over dozens of countries as a way to strong-arm political concessions that are not necessarily related to actual trade issues. Section 301 is the new legal fig leaf to cover Trump’s naked unilateralism.

Donald Trump and his White House team are determined to take back this lost power as part of his imperial presidency. But the question is: would that be good for U.S. trade policy? Is it beneficial to have our trade relations with dozens of countries dependent on the whim of a single, unpredictable man with an ego-driven authoritarian streak?


Steven Hill was policy director for the Center for Humane Technology, co-founder of FairVote, and political reform director at New America. See more of his writing at his Substack newsletter DemocracySOS.


Read More

Congress at sunset

America's national debt is projected to reach $45 trillion by 2029. Explore Congress's constitutional "Power of the Purse," federal spending, appropriations, and the policies contributing to rising deficits.

Bill Clark/Getty Images

Congress Must Enforce the Power of the Purse as Debt Soars

“No Money shall be drawn from the Treasury, but in Consequence of Appropriations made by Law” (Appropriations Clause, Article I, Section 9, Clause 7, U.S. Constitution). Congress’s “Power of the Purse” means the President cannot spend money or authorize expenditures unless Congress has passed a specific law funding it (Congress.gov).

According to the Congressional Budget Office (CBO) and the non-partisan Committee for a Responsible Federal Budget, the total federal debt held by Americans is on track to hit $40 trillion by the end of 2026. Currently, every resident in America carries a $122,642 share of this debt.

Keep ReadingShow less
​A Lebanese girl returns with her family to live amid the ruins of an apartment wrecked by Israeli strikes.

A Lebanese girl returns with her family to live amid the ruins of an apartment wrecked by Israeli strikes in the Houch neighborhood, after being displaced for weeks by war between Israel and the Iran-backed Hezbollah militia that has displaced 1.2 million Lebanese, on April 28, 2026, in Tyre, Lebanon.

Scott Peterson / Getty Images

Please Don't Feed the Warmongers

I was recently catching up with an old friend from my Navy Reserve Officer Training Corps days who told me about some young sailors he knew in Bahrain tasked with intercepting hostile drones. Critically, as highly disciplined professionals, they have become extraordinarily good at it. My friend and I, with over twenty years of active duty service as military officers between us, discussed the extent to which their competence and vigilance are keeping them, and other Americans deployed in the area, alive, all while their leadership in Washington treats war with an increasingly terrifying callousness.

As brave servicemembers risk their lives on the front lines, Trump brags about how much money he’s making as president. It is true that for those invested in the types of industries that thrive during armed conflict, this war in Iran is a windfall. Trump himself invested between $9.7 million and $24.3 million in arms manufacturers and Pentagon contractors in 2025. Why would he end the war?

Keep ReadingShow less
A father voting, with his young son standing by him, watching him.

Citizens cast their vote during the 2026 presidential runoff in Colombia on June 21, 2026 in Barranquilla, Colombia. Ivan Cepeda, candidate for the Pacto Historico party and Abelardo de la Espriella, candidate for the Salvación Nacional, face in a tight runoff to rule Colombia from 2026 to 2030.

Leonardo Castañeda/Getty Images

Colombia’s Election Matters—Especially to Ecuador and the U.S.

In a closely fought election on June 21, conservative outsider Abelardo De La Espriella prevailed over Iván Cepeda, an ally of current leftist president, Gustavo Petro. Central to the electorate’s choice were distinct policy proposals to fight criminality and the drug cartels, who control large swaths of Colombian territory. The policies president-elect De La Espriella will bring to the fight against these issues matter greatly, not only to Colombia, but to neighboring Ecuador and the United States.

Earlier in March, Ecuadorian President Noboa, desperate to gain traction in his own drug war, announced a partnership with the U.S. to conduct joint operations against drug cartels. The partnership quickly went awry. A New York Times investigation of the first strike indicates that what the joint militaries considered a drug camp was in fact a dairy farm, with no drug connection. Then, on March 17, Colombia accused Ecuador of bombing within its territory with U.S. involvement. These incidents resulted in U.S. lawmakers calling for a suspension of joint operations on May 13. Very quickly, the U.S. partnership has reopened the scars of the Plan Colombia era of the early 2000s, where an overly militaristic approach to the drug war funded by the U.S. resulted in human rights abuses and false positives.

Keep ReadingShow less
Adult grandson teaching his grandfather to use laptop, close-up.

Social Security faces a funding crisis by 2032 that could cut retirement benefits by 22%. Learn what's driving the shortfall and how it could be fixed.

Westend61 / Getty Images

Social Security Faces a 2032 Crisis with Deep Benefit Cuts Ahead

A financial tsunami of giant proportions is heading our way. And it is due to arrive in about six years. Policymakers have known about this tsunami for some time, but in June, we found out the Big Wave is taller than anyone knew.

That’s when the Social Security Trustees released their latest report on the financial health of the popular Social Security retirement program. According to the trustees’ report, the outlook is not good – Social Security’s solvency is in danger. By 2032, the Social Security fund will fall short by about $2.5 trillion of the money needed to pay the 52 million American retirees their full retirement benefits. Previously, it was thought that the tsunami would make landfall in 2034, but the finances are deteriorating faster than expected. If no presidential and congressional intervention is mounted, retirees will take about a 22 percent haircut, meaning any senior beneficiary who was receiving $3000 per month will see that chopped to about $2300 per month, a loss of about $8000 per year.

Keep ReadingShow less